Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits, Vector & Virus, Western Blot
Top VHL Recombinant Protein For Human
Von Hippel-Lindau (VHL) Protein Antagonist VH298 Improves Wound Therapeutic in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Issue- (HIF-) 1 Signalling.
The aim of the current analysis is to analyze the results of the VHL protein antagonist, VH298, on purposeful actions of fibroblasts and vascular endothelial cells and the results on the wound therapeutic course of in a streptozotocin-induced hyperglycaemic rat mannequin.
Strategies
HIF-1α and hydroxy-HIF-1α protein ranges in VH298-treated rat fibroblasts (rFb) had been measured by immunoblotting, rFb proliferation was detected by the CCK-Eight assay, and mRNA ranges of associated genes had been measured by quantitative RT-PCR. In vitro wound therapeutic was simulated by the scratch take a look at; angiogenesis was measured by the human umbilical vein endothelial cell (hUVEC) tube formation assay. VH298 or PBS was regionally injected into wounds in rat fashions with streptozotocbd tissues had been harvested, and haematoxylin-eosin (HE) and Masson trichrome staining and immunohistochemical processes had been carried out.
Human Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment
Outcomes
HIF-1α and hydroxy-HIF-1α ranges elevated in VH298-treated rFb, in a time- and dose-dependent method. Thirty micromolar VH298 may considerably enhance cell proliferation, angiogenesis, and gene expression of sort I collagen-αα
Conclusions
Taken collectively, VH298 activated the HIF-1 signalling pathway by stabilizing each HIF-1α and hydroxy-HIF-1α. VH298 enhanced rFb capabilities, promoted hUVEC angiogenesis, and accelerated wound therapeutic within the rat mannequin mimicking diabetes mellitus.
Rat Von Hippel Lindau Tumor Suppressor (vHL) ELISA Equipment

VHL Antibody |
MBS7122921-005mg |
MyBiosource |
0.05mg |
EUR 150 |
VHL Antibody |
MBS7122921-5x01mg |
MyBiosource |
5x0.1mg |
EUR 845 |
VHL Antibody |
MBS7124447-005mL |
MyBiosource |
0.05mL |
EUR 190 |
VHL Antibody |
MBS7124447-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
VHL Antibody |
MBS7124448-005mL |
MyBiosource |
0.05mL |
EUR 190 |
VHL Antibody |
MBS7124448-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
VHL antibody |
70R-9757 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Affinity purified rabbit polyclonal VHL antibody |
VHL antibody |
70R-34605 |
Fitzgerald |
100 ug |
EUR 294 |
|
Description: Purified Rabbit polyclonal VHL antibody |
VHL Antibody |
E18-6292-1 |
EnoGene |
50μg/50μl |
EUR 145 |
Description: Available in various conjugation types. |
VHL Antibody |
E18-6292-2 |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
VHL Antibody |
E19-6104 |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
VHL Antibody |
B8450-100ul |
Assay Biotech |
100μl |
EUR 217 |
Description: VHL Rabbit Polyclonal Antibody |
VHL Antibody |
B8450-50ul |
Assay Biotech |
50μl |
EUR 143.5 |
Description: VHL Rabbit Polyclonal Antibody |
VHL Antibody |
CSB-PA025852KA01HU- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
CSB-PA025852KA01HU-100ul |
Cusabio |
100ul |
EUR 466.8 |
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
VHL Antibody |
1-CSB-PA060067 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
VHL Antibody |
1-CSB-PA071125 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VHL Antibody |
32075 |
SAB |
100ul |
EUR 439 |
VHL Antibody |
32075-100ul |
SAB |
100ul |
EUR 302.4 |
VHL Antibody |
C30872-100ul |
Assay Biotech |
100μl |
EUR 217 |
Description: VHL Rabbit Polyclonal Antibody |
VHL Antibody |
C30872-50ul |
Assay Biotech |
50μl |
EUR 143.5 |
Description: VHL Rabbit Polyclonal Antibody |
VHL Antibody |
1-CSB-PA991849 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:50-1:200 |
VHL Antibody |
1-CSB-PA876839 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against VHL. Recognizes VHL from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000 |
VHL Antibody |
E90377 |
EnoGene |
100ul |
EUR 255 |
Description: Available in various conjugation types. |
VHL Antibody |
E312859 |
EnoGene |
200ul |
EUR 275 |
Description: Available in various conjugation types. |
VHL Antibody |
MBS2526109-006mL |
MyBiosource |
0.06mL |
EUR 230 |
VHL Antibody |
MBS2526109-012mL |
MyBiosource |
0.12mL |
EUR 310 |
VHL antibody |
MBS206608-005mL |
MyBiosource |
0.05mL |
EUR 260 |
VHL antibody |
MBS206608-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1300 |
VHL Antibody |
MBS8512326-005mg |
MyBiosource |
0.05mg |
EUR 235 |
VHL Antibody |
MBS8512326-01mLAF405M |
MyBiosource |
0.1mL(AF405M) |
EUR 465 |
VHL Antibody |
MBS8512326-01mLAF546 |
MyBiosource |
0.1mL(AF546) |
EUR 465 |
VHL Antibody |
MBS8512326-01mLAF750 |
MyBiosource |
0.1mL(AF750) |
EUR 465 |
VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma.
- Sporadic clear-cell renal cell carcinoma (ccRCC) is related with mutations within the VHL gene, upregulated mammalian goal of rapamycin (mTOR) exercise and glycolytic metabolism. Right here, we analyze the impact of VHL mutational standing on the expression stage of mTOR, eIF4E-BP1, AMPK, REDD1, and PDK3 proteins.
pGF-AP1-mCMV-EF1-Puro (293 secure cell line)
- Complete proteins had been remoted from 21 tumorous samples with biallelic inactivation, 10 with monoallelic inactivation and 6 tumors with a wild-type VHL (wtVHL) gene obtained from sufferers who underwent complete nephrectomy. The expressions of goal proteins had been assessed utilizing Western blot.Expressions of mTOR, eIF4EBP1 and AMPOkay had been VHL impartial.
- Tumors with monoallelic inactivation of VHL underexpressed REDD1 compared to wtVHL tumors (P = 0.042), tumors with biallelic VHL inactivation (P < 0.005) and management tissue (P = 0.004). Moreover, REDD1 expression was larger in tumors with VHL biallelic inactivation than in management tissue (P = 0.008). Solely in wt tumor samples PDK3 was overexpressed compared to tumors with biallelic inactivation of VHL gene (P = 0.012) and controls (P = 0.016). In wtVHL ccRCC, multivariate linear regression evaluation revealed that 97.4% of variability in PDK3 expression might be defined by variations in AMPK quantity.Expressions of mTOR, eIF4EBP1 and AMPK had been VHL impartial.
- Now we have proven for the primary time VHL dependent expression of PDK3 and we offer extra proof that VHL mutational standing impacts REDD1 expression in sporadic ccRCC.
Gene Knock-Out HR Concentrating on Vector w/Single Choice Marker (Blasticidin) and Destructive Choice (TK) Towards Random Integration
-
VHL sufferers (n = 339) had been recruited and grouped primarily based on mutation sorts: HIF-α binding web site missense (HM) mutations, non-HIF-α binding web site missense (nHM) mutations, and truncating (TR) mutations. Age-related dangers of VHL-associated tumors and affected person survival had been in contrast.
-
Missense mutations conferred an elevated danger of pheochromocytoma (HR = 1.854, p = 0.047) in contrast with truncating mutations. The danger of pheochromocytoma was decrease within the HM group than within the nHM group (HR = 0.298, p = 0.003) however was related between HM and TR teams (HR = 0.901, p = 0.810).
MUC16 CRISPR Knock Out Human OVCAR3-A1 Cell Line |
T6230 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
Ccl2 CRISPR Knock Out CT26 Cell Line |
T9611 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
CXCL8 CRISPR Knock Out L3.6pl Cell Line |
T6220 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
CXCL1 CRISPR Knock Out L3.6pl Cell Line |
T6221 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
SIRT CRISPR Knock Out Human HepG2 Cell Line - Clone T3-6 |
T6804 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
PRSS21 CRISPR Knock Out Human OVCAR8 Cell Line - Clone T2 C8 |
T6811 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
mAdrb2 CRISPR Knock Out B16 Cell Line (T1-10) |
T9775 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
TREM2 CRISPR Knock Out Human THP-1 Cell Line - Clone T1-9 |
T6810 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
PTPN6 CRISPR Knock Out Human THP-1 Cell Line - Clone T3-1 |
T6813 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
MSLN CRISPR Knock Out Human OVCAR3-A1 Cell Line - Clone T2 C4 |
T6820 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
NR2F6 CRISPR Knock Out Human Jurkat E6.1 Cell Line - Clone T3-10 |
T6822 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
NUAK2 CRISPR Knock Out 293T Cell Line - Clone T3 #41 |
T6801 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
Aldh2 CRISPR Knock Out L929 Cell Line - Clone T3-20 |
T9692 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
hPIM1 CRISPR Knock Out SACC-83 Cell Line-T3-9 |
T9787 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
Dcx CRISPR Knock Out C6 Cell Line (Rat) - Clone sg4-1 |
T9624 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
GLT1 CRISPR Knock Out Rat AST Cell Line - Clone T2-1 |
T9678 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
PTPN11 CRISPR Knock Out NIH/3T3 Cell Line - Clone T4-9 |
T6803 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
METTL3 CRISPR Knock Out Caki-1 Cell Line - Clone T2-16 |
T9623 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
Nacc1 CRISPR Knock Out ID8 Cell Line (Mouse) - Clone T1-23 |
T9627 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
osbpl2 CRISPR Knock Out NIH/3T3 Cell Line - T1 Polyclonal Pool |
T9682 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
CARMIL1 CRISPR Knock Out Immortalized Human Gingival Fibroblast - hTERT Cell Line - T1-2 |
T6825 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
Aifm1 CRISPR Knock Out Mouse L929 Cell Line - Clone T2-15-3 |
T9674 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
SEC61G CRISPR Knock Out HCC-LM3 Cell Line - Clone T2-17-5 |
T9746 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
Cell line gene knock-in and knock-out |
S301 |
101Bio |
- |
EUR 15000 |
293/GFP Cell Line |
AKR-200 |
Cell Biolabs |
1 vial |
EUR 388 |
Description: Fluorescence |
Human VHL knockdown HAP1 Cell Line |
ABC-KD16757 |
AcceGen |
1 vial |
Ask for price |
Description: This cell line is engineered by our optimized transduction of the specific shRNA with lentivirus |
Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T3-3 |
T9529 |
ABM |
1x10^6 cells/1.0ml |
EUR 3950 |
Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T1-19 |
T9511 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
Stable Mouse Myeloid-derived Suppressor-like LAL Knock Out (HD1B) Cell Line |
T3187 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
BRCA1 CRISPR Stable Knockout Human Fibroblast Cell Line |
T6245 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
PTPRA CRISPR Knockout Immortalized Human Lung Fibroblast Cell Line |
T6827 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
293AD Cell Line |
AD-100 |
Cell Biolabs |
1 vial |
EUR 308 |
Description: N/A |
293AAV Cell Line |
AAV-100 |
Cell Biolabs |
1 vial |
EUR 340 |
Description: N/A |
293LTV Cell Line |
LTV-100 |
Cell Biolabs |
1 vial |
EUR 340 |
Description: N/A |
Human CRISP1 knockout cell line |
ABC-KH3569 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRISP2 knockout cell line |
ABC-KH3570 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRISP3 knockout cell line |
ABC-KH3571 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Acan CRISPR Knockout RCS Cell Line (Rat) |
T3000 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
T47D/GFP Cell Line |
AKR-208 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
A549/GFP Cell Line |
AKR-209 |
Cell Biolabs |
1 vial |
EUR 388 |
Description: Fluorescence |
HeLa/GFP Cell Line |
AKR-213 |
Cell Biolabs |
1 vial |
EUR 388 |
Description: Fluorescence |
Human CRISPLD1 knockout cell line |
ABC-KH3572 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISPLD1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRISPLD2 knockout cell line |
ABC-KH3573 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISPLD2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
NIH3T3/GFP Cell Line |
AKR-214 |
Cell Biolabs |
1 vial |
EUR 388 |
Description: Fluorescence |
Human CRISP1 knockdown cell line |
ABC-KD3569 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISP1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
Human CRISP2 knockdown cell line |
ABC-KD3570 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISP2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
Human CRISP3 knockdown cell line |
ABC-KD3571 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISP3 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
Human VHLL knockout cell line |
ABC-KH16758 |
AcceGen |
1 vial |
Ask for price |
Description: Human VHLL knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
MCF-7/Luc Cell Line |
AKR-234 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
SKOV-3/Luc Cell Line |
AKR-232 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
OVCAR-5/RFP Cell Line |
AKR-254 |
Cell Biolabs |
1 vial |
EUR 686.4 |
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
AST-7001 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 6 month |
Human CRISPLD1 knockdown cell line |
ABC-KD3572 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISPLD1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
Human CRISPLD2 knockdown cell line |
ABC-KD3573 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRISPLD2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
GFAT1 CRISPR Stable Knockout H1299 Cell Line |
T6199 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
EDC4 CRISPR Stable Knockout HEK293T Cell Line |
T6241 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
Human VHLL knockdown cell line |
ABC-KD16758 |
AcceGen |
1 vial |
Ask for price |
Description: Human VHLL knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
DJ-1 CRISPR Stable Knockout HeLa Cell Line |
T6181 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
PDPN CRISPR Stable Knockout COS-7 Cell Line |
T6039 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
PD-L1 CRISPR Stable Knockout CT26 Cell Line |
T6237 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
PD-L1 CRISPR Stable Knockout MC38 Cell Line |
T6149 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
LIMD1-/- CRISPR Stable Knockout HeLa Cell Line |
T6357 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
SLC35A1 CRISPR Stable Knockout CHO-S Cell Line |
T6040 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
CXCL1 & CXCL8 CRISPR Double Knockout L3.6pl Cell Line |
T6047 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
TARGATT? Knock-in iPSC Generation (Master Cell Line) |
AST-1100 |
Applied StemCell |
1 vial of 1X10^6 cells |
Ask for price |
Description: 6 month |
PLN Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
iPS41 |
ALSTEM |
1 Vial |
EUR 2268 |
AXL CRISPR Stable Knockout HT1080 (1-IV) Cell Line |
T6232 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
AXL CRISPR Stable Knockout HT1080 (3-II) Cell Line |
T6233 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
LRP1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
iPS31 |
ALSTEM |
1 Vial |
EUR 2268 |
AFF2 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
iPS61 |
ALSTEM |
1 Vial |
EUR 2268 |
ABCA7 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
iPS21 |
ALSTEM |
1 Vial |
EUR 2268 |
KCNK3 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
iPS51 |
ALSTEM |
1 Vial |
EUR 2268 |
LLGL1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
iPS71 |
ALSTEM |
1 Vial |
EUR 2268 |
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
RV-101 |
Cell Biolabs |
1 vial |
EUR 648 |
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
RV-103 |
Cell Biolabs |
1 vial |
EUR 648 |
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
RV-102 |
Cell Biolabs |
1 vial |
EUR 648 |
Total Protein - Murine Embryonic Stem Cell Line D3 |
CBA-305 |
Cell Biolabs |
500 ?g |
EUR 414 |
Description: - Isolated from mouse ES-D3 cell line
- Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer
|
TARGATT? Knock-in CHO Generation Kit (Master Cell Line) |
AST-1200 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line) |
AST-1300 |
Applied StemCell |
1 Kit |
Ask for price |
Description: 12 month |
PTPN6 Stable Knocked Out THP-1 Cell Line |
T6216 |
ABM |
1x10^6 cells / 1.0 ml |
EUR 3950 |
Human CRIM1 knockout cell line |
ABC-KH3563 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRIM1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRIP1 knockout cell line |
ABC-KH3564 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRIP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRIP2 knockout cell line |
ABC-KH3565 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRIP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRIP3 knockout cell line |
ABC-KH3566 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRIP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRIPT knockout cell line |
ABC-KH3568 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRIPT knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
Human CRIPAK knockout cell line |
ABC-KH3567 |
AcceGen |
1 vial |
Ask for price |
Description: Human CRIPAK knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
-
Sufferers within the nHM group had the next danger of pheochromocytoma (HR = 3.447, p < 0.001) and decrease dangers of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than these within the mixed HM and TR (HMTR) group.
-
Furthermore, nHM mutations had been independently related to better general survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations.
-
The modified genotype-phenotype correlation hyperlinks VHL gene mutation, substrate binding web site, and phenotypic range (penetrance and survival), and offers extra correct data for genetic counseling and pathogenesis research.